Phaseline

Targets › CANX

CANX (Calnexin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology.

Calcium-binding protein that interacts with newly synthesized monoglucosylated glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. (UniProt, P27824)

Open in Phaseline: the race on CANX, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NanoEchoNanoEcho Particle-1 (NEP-1, Ferumoxtran)
Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles - iron oxide contrast agent
CANXPhase 2Healthy Volunteers–

Conditions

Healthy Volunteers (1)

Modalities

small molecule (1)

Companies

NanoEcho (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.